Zoë Folchman-Wagner, PhD is a Lecturer in the Natural and Applied Sciences Department at Bentley University. Zoë received a BS in Chemistry from New York University and a BE in Biomedical Engineering from Stevens Institute of Technology. She also has a MSE in Bioengineering from the University of Pennsylvania and a PhD in Pharmaceutical Sciences from the University of Southern California School of Pharmacy, where her dissertation explored the design and use of novel pH-response protein nanoparticles for targeted drug delivery to the tumor microenvironment. Her current research focuses on innovation systems for pharmaceuticals and assessments of pedagogical innovations, and she teaches courses on pharmacology, human biology, and the microbiome.
By this expert
Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.